Thomas Ormsby

• Repurposing transferrin receptor 1 (TfR1)-binding aptamers as targeting ligands for systemic siRNA delivery
• Achieves selective and durable siRNA activity in skeletal muscle following a single systemic dose
• Establishes aptamer–siRNA conjugates as a promising platform for next-generation targeted oligonucleotide therapeutics

An interactive panel discussion bringing together experts developing next-generation delivery technologies to debate the future of transferrin receptor targeting, emerging alternatives and the scientific challenges that remain in achieving effective delivery

• Compare the strengths and limitations of IgG, Fab, VHH and bispecific transferrin receptor targeting strategies to understand where each approach is demonstrating the greatest translational potential
• Debate whether continued optimisation of transferrin receptor biology is enough or if the field must identify new receptors and targeting mechanisms to unlock the next generation of oligonucleotide-based therapeutics
• Put your questions directly to the panel and gain practical insights into the opportunities, remaining barriers and future direction of transferrin receptor delivery